The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.

被引：1
|
作者：
Bao, Kelvin K. H. [1 ]
Sutanto, Leone [1 ]
Tse, Shirley S. W. [1 ]
Cheung, Ka Man [1 ]
Chan, Jeffrey C. H. [1 ]
机构：
[1] Queen Elizabeth Hosp, Dept Clin Oncol, Kowloon, Hong Kong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.1052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1052
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Efficacy of first line CDK4/6 inhibitors in HER2-low vs HER2-zero, hormone receptor positive, HER2 negative metastatic breast cancer
    Sanchez-Bayona, Rodrigo
    Teran, Santiago
    De Torre, Ana Sanchez
    Alva, Manuel
    Lema, Laura
    Manso, Luis
    Toledo, Estefania
    Roncero, Ana Maria
    Merino, Cristina
    Martinez, Mario
    Parrilla, Lucia
    Ciruelos, Eva
    Tolosa, Pablo
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [2] Hormone receptor-positive HER2-low metastatic breast cancer (mBC): evolution of HER2 status after CDK4/6 inhibitor treatment
    de Nonneville, Alexandre
    Finetti, Pascal
    Boudin, Laurys
    Usclade, Lucas
    Mescam, Lenaig
    Durieux, Emeline
    Boucraut, Agathe
    Viret, Frederic
    Mamessier, Emilie
    Goncalves, Anthony
    Bertucci, Francois
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [3] Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
    Boyle, Frances
    Beith, Jane
    Burslem, Katie
    de Boer, Richard
    Hui, Rina
    Lim, Elgene
    McCarthy, Nicole
    Redfern, Andrew
    Woodward, Natasha
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 3 - 11
  • [4] Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
    Migliaccio, Ilenia
    Leo, Angela
    Galardi, Francesca
    Guarducci, Cristina
    Fusco, Giulio Maria
    Benelli, Matteo
    Di Leo, Angelo
    Biganzoli, Laura
    Malorni, Luca
    [J]. CANCERS, 2021, 13 (11)
  • [5] The association of hormone receptor expression level and clinical efficacy of CDK4/6 inhibitor in hormone receptor-positive, HER2-negative metastatic breast cancer
    Bao, Kelvin K. H.
    Wong, Carol H. Y.
    Yung, Jackie
    Tam, Venus
    Cheung, Ka Man
    Chan, Jeffrey C. H.
    Yiu, Harry H. Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer
    Zhang, Cui
    Zhou, Fulin
    Zou, Jiali
    Fang, Yanman
    Liu, Yuncong
    Li, Libo
    Hou, Jing
    Wang, Guanghui
    Wang, Hua
    Lai, Xiaolian
    Xie, Lu
    Jiang, Jia
    Yang, Can
    Huang, Yisidan
    Chen, Yingji
    Zhang, Hanqun
    Li, Yong
    [J]. FRONTIERS IN ONCOLOGY, 2024, 13
  • [7] The Effects of HER2 on CDK4/6 Activity in Breast Cancer
    Sinclair, William D.
    Cui, Xiaoyan
    [J]. CLINICAL BREAST CANCER, 2022, 22 (03) : E278 - E285
  • [8] A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor
    Roy, Tina
    Barrows, Elizabeth
    Mainor, Candace
    Collins, Julie
    Lynce, Filipa
    Isaacs, Claudine
    Pohlmann, Paula R.
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2023, 33
  • [9] Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)
    Laguna, J. C.
    Braso-Maristany, F.
    Pascual, T.
    Rodriguez Hernandez, A.
    Chic, N.
    Schettini, F.
    Sanfeliu Torres, E.
    Gonzalez-Farre, B.
    Martinez, D.
    Galvan, P.
    Diez-Guardia, V.
    Adamo, B.
    Vidal, M.
    Guillen Sacoto, M. C.
    Moreno, R.
    Prat, A.
    Munoz, M.
    Martinez-Saez, O.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S69 - S70
  • [10] Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape
    Redfern, Andrew
    Burslem, Katie
    Woodward, Natasha
    Beith, Jane
    Mccarthy, Nicole
    De Boer, Richard
    Bell, Richard
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 19 - 31
12345